Skip to main content

Table 5 Vaccine effectiveness (VE) against influenza subtypes among the elderly: comparison of results from this present study with results from observational studies in Europe using the test-negative design, seasons 2010/11-2012/13

From: Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany

Country [ref]

Age-group

 

VE§in % (95% CI)

VE§in % (95% CI)

VE§in % (95% CI)

 

(Years)

VE-analysis

A(H1N1)pdm

A(H3N2)

B

Season 2010/11

   

This study

≥60

Crude

76 (70–81)

-

84 (76–90)

  

Adjusted

-

-

-

Europe (I-MOVE)1 [38]

≥60

Crude

73 (48–86)

-

48 (−2-73)

  

Adjusted

72 (27–90)

-

56 (−38-86)

UK [42]

≥65

Crude

-

-

-

  

Adjusted

70 (0–85)2

-

65 (20–80)2

Spain I [40]

≥50

Crude

67 (27–85)3

-

-

  

Adjusted

69 (0–91)3

-

-

Spain II [43]

≥60

Crude

60 (20–80)4

-

-

  

Adjusted

59 (16–76)4

-

-

Spain III [45]

≥65

Crude

41 (−36-74)5

-

-

  

Adjusted

-

-

-

Spain IV [46]

≥65

Crude

54 (−18-82)6

  
  

Adjusted

-

  

Germany [17]

≥60

Crude

89 (1–99)3

-

-

  

Adjusted

92 (−67-100)3

-

-

Season 2011/12

   

This study

≥60

Crude

87 (14–100)

−9 (−59-26)

74 (55–86)

  

Adjusted

-

-

-

Europe (I-MOVE)1 [39]

≥60

Crude

-

6 (−41-38)

-

  

Adjusted

-

15 (−33-46)

-

UK [41]

≥65

Crude

-

-

-

  

Adjusted

-

48 (−50-82)

-

Spain I [49]

≥65

Crude

-

4 (−106-55)7

-

  

Adjusted

-

19 (−146-73)7

-

Spain II8 [47]

≥65

Crude

-

26 (−69-78)

-

  

Adjusted

-

-

-

Season 2012/13

    

This study

≥60

Crude

74 (69–79)

39 (13–58)

73 (68–77)

  

Adjusted

-

-

-

Europe (I-MOVE)1 [37]

≥60

Crude

59 (14–80)

37 (−13-65)

44 (9–66)

  

Adjusted

-

-

-

UK [44]

≥65

Crude

-

-

-

  

Adjusted

 

−14 (−206-57)

65 (18–85)

Denmark [35]

≥65

Crude

-

−19 (−52-6)

64 (17–84)

  

Adjusted

-

−11 (−41-14)

69 (26–87)

Lithuania8 [48]

≥60

Crude

92 (−55-100)9

  
  

Adjusted

-

  

Portugal8 [33]

≥60

Crude

80 (19–95)10

-

-

  

Adjusted

-

-

-

Multicenter11 [34]

≥65

Crude12

34 (−22-64)

46 (−16-75)

46 (23–63)

  

Adjusted

13 (−68-55)

39 (−40-73)

41 (12–61)

  1. VE, vaccine effectiveness.
  2. §VE point estimates were rounded off to whole numbers.
  3. 1I-MOVE pooled data from other European countries; therefore, overlapping with some of the individual studies from the same season is likely.
  4. 2approx. VE since data for this age group were presented as figures only.
  5. 3VE against all influenza types; >80% of all subtypes identified were H1N1.
  6. 4VE against all-type influenza hospitalization; 76% of all subtypes identified were H1N1.
  7. 5VE against all-type hospitalization; 95% of all subtypes identified were H1N1.
  8. 6VE against all influenza types; 56% of all subtypes identified were H1N1, 41% were B.
  9. 7VE against all influenza cases; 92% of all subtypes identified were H3N2.
  10. 8Data extracted from the study of Darvishian et al. [31].
  11. 9VE against all influenza types; distribution among the whole study population: 41% H1N1, 40% B, 19% H3N2.
  12. 10VE against all influenza types; distribution among the whole study population: 53% H1N1, 43% B.
  13. 11VE against hospitalization; data collected in Spain, France and in the Russian Federation.
  14. 12adjusted for study site.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us